King's Research Portal

DOI:

[10.2174/0929867327666200721161840](https://doi.org/10.2174/0929867327666200721161840)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Laws, M., Surani, Y. M., Hasan, M., Chen, Y., Jin, P., Al-Adhami, T., Chowdhury, M., Imran, A., Rahman, K. M., Jamshidi, S., Psaltis, I., & Nahar, K. S. (2020). Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19. *Current Medicinal Chemistry*, 28(19).
<https://doi.org/10.2174/0929867327666200721161840>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19

Running Title: Trends in Small-Molecule Therapeutics for COVID-19

Mark Laws, Yasmin M. Surani, Md. Mahbub Hasan, Yiyuan Chen, Peiqin Jin, Taha Al-Adhami, Madiha Chowdhury, Aqeel Imran, Ioannis Psaltis, Shirin Jamshidi, Kazi S. Nahar and Khondaker Miraz Rahman*

Institute of Pharmaceutical Sciences, School of Cancer and Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK.

*Corresponding author. E-mail: k.miraz.rahman@kcl.ac.uk, tel.: +44 207 848 1891.

Keywords: COVID-19; SARS-CoV-2; coronavirus; drug discovery; small-molecule therapeutics; clinical trials

Abstract

The novel coronavirus (SARS-CoV-2) pandemic has created a global public health emergency. The pandemic is causing substantial morbidity, mortality and significant economic loss. Currently, no approved treatments for COVID-19 are available, and it is likely to take at least 12-18 months to develop a new vaccine. Therefore, there is an urgent need to find new therapeutics that can be progressed to clinical development as soon as possible. Repurposing regulatory agency-approved drugs and experimental drugs with known safety profiles can provide important repositories of compounds that can be fast-tracked to clinical development. Globally, over 500 clinical trials involving repurposed drugs have been registered, and over 150 have been initiated, including some backed by the World Health Organisation (WHO). This review is intended as a guide to research into small-molecule therapies to treat COVID-19; it discusses the SARS-CoV-2 infection cycle and identifies promising viral therapeutic targets, reports on a number of promising pre-approved small-molecule drugs with reference to over 150 clinical trials worldwide, and offers a perspective on the future of the field.

Graphical Abstract

1. INTRODUCTION

COVID-19 (coronavirus disease 2019) is an infectious disease caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus that was first identified in Wuhan, China in December 2019. The rapid evolution of the COVID-19 crisis from regional outbreak to global pandemic has caught governments and healthcare systems off guard [1]. With over 10 million confirmed cases as of the 28th of June [2], treatments for SARS-CoV-2 infection and COVID-19 are urgently needed. Symptoms of the disease typically include fever, dry cough and dyspnoea; less common are malaise, myalgia, anosmia, nausea and pain in the head, throat and/or abdomen. Patients suffering from severe cases of COVID-19 may also present with symptoms such as respiratory distress, tachypnoea and hypoxia. The latter cases can progress from viral pneumonia to acute respiratory distress syndrome (ARDS), multiple organ failure and death [1].

SARS-CoV-2 belongs to a family of viruses known as the coronaviruses, members of the order *Nidovirales* that are spread broadly among humans, different domestic/wild animals and birds and can cause respiratory, hepatic and neurological diseases [3]. Among the seven coronavirus species which are capable of infecting humans, four viruses (229E, OC43, NL63 and HKU1) are common respiratory viruses that produce common cold symptoms but can also cause pneumonia. Three zoonotic viruses – SARS-CoV (severe acute respiratory syndrome coronavirus), MERS-CoV (Middle East respiratory syndrome coronavirus) and, the most recent to emerge, SARS-CoV-2 – can cause fatal respiratory illness in humans [4, 5]. Recent studies suggest that SARS-CoV-2 is more contagious than SARS-CoV [6].

The scientific community have responded to the threat posed by SARS-CoV-2 with rapid identification and subsequent publication of crystal and cryo-EM structures of important SARS-CoV-2 drug targets, including the spike protein [7], main protease [7] and Nsp15 ribonuclease [8]. However, targeted approaches to designing new drugs for clinical use will take considerable time. Rapid repurposing of clinically-approved small-molecule drugs in randomised trial-led efforts to identify effective COVID-19 medications may buy time with which to develop investigational treatments.

1.1. The SARS-CoV-2 Virus Infection Cycle

SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA betacoronavirus. Its RNA genome encodes three major surface proteins termed the spike (S), membrane (M), and envelope (E) proteins [9]. A fourth gene

encodes the nucleocapsid (N) [10]. The spike protein forms homotrimers on the viral surface [11] and is comprised of two domains, an N-terminal S1 domain that mediates receptor binding [12] and a C-terminal, transmembrane S2 domain for membrane fusion [9, 11]. The SARS-CoV-2 infection cycle (Figure 1) begins with the recognition of angiotensin-converting enzyme 2 (ACE2) on the host cell surface by the spike protein [13]. Interaction of the spike protein with ACE2 is thought to trigger a conformational change in the former, revealing a site between the S1 and S2 domains that can be cleaved by host cell membrane proteases. Now activated for membrane fusion, the cleaved S2 subunit inserts into the host cell membrane *via* its N-terminal fusion peptide so that it is connected to both the viral and cell membranes. The N- and C-terminal heptad repeats of the S2 subunit then fold to form a six-helix bundle, contracting the S2 subunit and bringing the two membranes into close proximity, whereupon they fuse [9].

Following a successful recognition event, virus internalisation can occur either by direct fusion with the plasma membrane or by endocytosis [13]. In the case of direct fusion, the host protease responsible for cleavage of the S1 and S2 domains is thought to be transmembrane protease serine 2 (TMPRSS2), whereas in endocytosis the cysteine protease cathepsin L is thought to be responsible [9]. In addition, it has recently become apparent that SARS-CoV-2 contains sites that can be processed by furin-like proteases; since furin is widely expressed in different cell types, this could increase the cell tropism of the virus beyond the respiratory and digestive systems [11, 14]. Fusion of the viral and cellular membranes triggers the release of viral genomic RNA into the host cell cytoplasm [13] and uncoating of the viral nucleocapsid [15]. If not targeted for degradation in the cytoplasm, the viral RNA then attaches to the host ribosome, whereupon the viral genes ORF1a and ORF1ab are translated into polyproteins [12] pp1a and pp1ab [1], respectively. These polyproteins are processed by the coronavirus main protease (M^{pro}) and a papain-like protease (PL^{pro}), both cysteine proteases [12, 16]. M^{pro} is also known as 3C-like protease ($3CL^{pro}$) because of its similar cleavage site specificity to the 3C protease ($3C^{pro}$) found in picornaviruses [17]. Proteolysis gives rise to a number of non-structural proteins which form the replicase-transcriptase, the only protein translated directly from the viral genome [15]. Alongside an ATP-dependent RNA helicase and various cofactors [15], this RNA-dependent RNA polymerase copies the viral RNA in membrane-associated replication-transcription complexes [1, 18] *via* negative-strand intermediates [13]. Copies of the full-length genomic RNA and a set of sub-genomic mRNAs are produced [13], the latter determined by transcriptional regulatory sequences located between open reading frames (ORFs) [1].

Once the replicase-transcriptase has replicated the viral genome and transcribed mRNAs, the sub-genomic mRNA templates are used for translation of structural and accessory viral proteins [13, 15], a process which occurs on the endoplasmic reticulum [15]. The full-length viral RNA is encapsidated and assembles with spike, envelope and membrane proteins in the endoplasmic reticulum-Golgi intermediate compartment [15]. At this stage, post-translational modifications will have occurred, such as S protein trimerization and glycosylation [9] and vesicles move to the plasma membrane for release of infectious virus particles from the host cell *via* exocytosis [15]. Upon viral release from the host cell, viral particles can be eliminated by a specific adapted immune response so that the disease does not progress in severity; if this does not happen, however, continued viral propagation downregulates ACE2, dysregulating the renin-angiotensin system and causing a cytokine storm which can lead to a host inflammatory response and ARDS (NCT04344041) [19].

1.2. Targeting the SARS-CoV-2 Virus with Small-Molecule Therapies

The severity of the current COVID-19 global pandemic necessitates immediate and decisive action to counter the threat posed by the SARS-CoV-2 virus. To this end, various different approaches for disrupting the SARS-CoV-2 infection cycle have been proposed using previously-approved drugs. Each of the structural and non-structural proteins encoded by its RNA genome are potential targets for existing antiviral agents [20] since many SARS-CoV-2 proteins have a high degree of sequence similarity to their SARS-CoV and MERS-CoV homologues [12].

Viral entry inhibitors are molecules able to interfere with either receptor recognition or spike protein proteolysis. This could involve drugs that target the spike protein, ACE2 inhibitors or inhibitors of host cell proteases like TMPRSS2, cathepsin L or furin, though combinations of protease inhibitors may be necessary to overcome the seemingly independent viral entry mechanisms. A high resolution crystal structure of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein with ACE2 has been published and has provided an important target to screen FDA- and EMA-approved drugs against to identify clinical candidates (Figure 2) [21]. Candidates that have been developed in the past for SARS-CoV or MERS-CoV may require more development beyond straightforward drug repurposing since the S1 subunit receptor binding domain in SARS-CoV-2 has only 73.5% sequence identity with its SARS-CoV counterpart [12]. Viral entry inhibitors are desirable because the opportunity for the virus to acquire resistance to these agents is minimal [22].

Viral replication inhibitors are another viable strategy, since the crystal structure of SARS-CoV-2 M^{pro} has been published [7] (Figure 2) and it shares 96% sequence identity with the corresponding enzyme in SARS-CoV. The SARS-CoV-2 RNA-dependent RNA polymerase is another promising target for drug repurposing since it also shares 96% sequence identity with the SARS-CoV homologue [12]. While PL^{pro} only has 83% sequence identity with its SARS-CoV homologue, active site conservation means it too is a promising target for drug repurposing [12]. Other possible targets include the viral helicase enzyme [23], 3'-to-5' exonuclease, endoRNase, 2'-O-ribose methyltransferase [24] and Nsp15 [8]. The structures of SARS-CoV-2 non-structural proteins have also been published [25] and it is expected that the crystal or cryo-EM structures of other targets will be published soon.

Viral release inhibitors are compounds capable of preventing the release of viral particles from host cells. While few agents have currently been identified that inhibit this step of the SARS-CoV-2 infection cycle, this approach has proven successful before in the case of the neuraminidase inhibitors, such as oseltamivir, which bind the membrane-anchored neuraminidase enzyme found in influenza viruses to prevent release of progeny viruses from infected cells [26]. With respect to SARS-CoV-2, the envelope protein may represent a promising target due to its role in viral release as a viroporin [27].

Immune response modulators are also necessary to combat the virus-induced lung inflammation that causes life-threatening respiratory disorders in severe cases of SARS-CoV-2 infection. ARDS is the major cause of death in clinical cases of COVID-19 [28, 29], caused by the uncontrollable activation of the antiviral immune response. Since this abnormal inflammatory response is mediated by macrophages and granulocytes, immune suppression *via* cytokine inhibitors can help in managing it. Various cytokines including IL-6 and TNF- α have been implicated in this immune response [19], with IL-6 thought to be responsible for cytokine release syndrome (CRS) which can lead to multiple organ failure [1, 30, 31]. High doses of corticosteroids have been traditionally considered effective in retarding multiple organ failure and decreasing ARDS-induced mortality, though their use to treat COVID-19 patients remains a matter of debate [32, 33]. Alternative approaches to the issue of SARS-CoV-2-induced ARDS must therefore be considered.

2. VIRAL ENTRY INHIBITORS

2.1. Spike Protein-Targeting Drugs

Umifenovir (Arbidol®; Figure 3), an antiviral medication used to treat influenza virus infections and approved for use in Russia and China [34], has been demonstrated to effectively inhibit SARS-CoV *in vitro* [35] and MERS-CoV [36] through disrupting virus-cell membrane fusion to block viral entry [37]. Although it appears to have a relatively low selectivity index (SI; CC_{50}/EC_{50}) against SARS-CoV-2 *in vitro* (SI >3.7 in Vero E6 cells; $EC_{50} = 10.7 \mu M$, $CC_{50} = >40 \mu M$, multiplicity of infection (MOI) 0.002) [38], variation in CC_{50} s between different cell lines (8 $\mu g/mL$ to 115 $\mu g/mL$) [39-41] has previously been noted. Work by Wu *et al.* would appear to confirm a similar mode of action against SARS-CoV-2; docking of umifenovir against possible drug target within SARS-CoV-2 indicated it would interact most favourably with the spike protein with an mfScore of -145.125 [36]. Touret *et al.* report an EC_{50} for umifenovir against SARS-CoV-2 of 10.7 μM [38]. Umifenovir is currently set to be investigated in a number of phase 4 clinical trials in China and Iran both as a monotherapy (NCT04260594, NCT04255017 and NCT04286503) and in combination with other therapies (NCT04254874 and NCT04350684) for treatment of patients with COVID-19. However, a retrospective study of 81 COVID-19 patients suggests that umifenovir is not an effective SARS-CoV-2 antiviral treatment [42].

Nitric oxide (GeNOsyl®, INOmax®, Noxivent™; Figure 3), a colourless gas known to have important roles in a number of different biological processes, has previously been shown to inhibit the replication of SARS-CoV. It achieves this through two distinct mechanisms; by reducing the palmitoylation of nascently expressed spike protein and thus interfering with receptor binding, and by reducing viral RNA production [43]. During the 2002-2004 SARS-CoV outbreak, low dose nitric oxide (<30 ppm) was found to reverse pulmonary hypertension, improve severe hypoxia and shorten the duration of ventilatory support needed in SARS-CoV-infected patients relative to a control group (NCT04305457). LC_{50} s are reported to be 315 ppm in rabbits, 320 ppm in mice and 854 ppm in rats, from which the National Institute for Occupational Safety and Health (NIOSH) has set an IDLH (Immediately Dangerous to Life or Health) value of 100 ppm for humans [44]. Nitric oxide is the subject of multiple planned phase 1-3 clinical trials in the US (NCT04398290, NCT04421508, NCT04397692, NCT04388683, NCT04305457, NCT04306393, NCT04312243 and NCT04338828) and Canada (NCT03331445 and NCT04383002) for the treatment of COVID-19 at concentrations ranging from 20 ppm to 300 ppm; doses of the drug in excess of the aforementioned IDLH value will be restricted to short periods of time (15-30 minutes, up to twice daily).

2.2. Angiotensin-Converting Enzyme 2-Targeting Drugs

The use of both angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) for the treatment of SARS-CoV-2 infections remains controversial; while their use may block viral entry into cells through interfering with the prerequisite virus-ACE2 interaction, some experimental models have found these drugs to prompt increased ACE2 expression in several organs which could exacerbate the viral infection. Trials in the US (NCT04338009) and Ireland (NCT04330300) have been planned to investigate this area further; the latter, a 2,414-person phase 4 clinical trial at University Hospital Galway (NCT04330300), will evaluate the ACEIs **captopril** (Capoten®), **lisinopril** (Prinivil®), **enalapril** (Vasotec®), **perindopril** (Coversyl®), **ramipril** (Altace®), **trandolapril** (Mavik®), **fosinopril** (Monopril®), **quinapril** (Accupril®) and **benazepril** (Lotensin®) (Figure 4) and ARBs **irbesartan** (Avapro®), **candesartan** (Atacand®), **eprosartan** (Teveten®), **losartan** (Cozaar®), **olmesartan** (Benicar®), **telmisartan** (Micardis®) and **valsartan** (Diovan®) (Figure 5). Further phase 1-4 trials of some of these drugs are planned and/or recruiting participants in the Netherlands (NCT04335786), Pakistan (NCT04343001), Egypt (NCT04345406) and the US (NCT04328012, NCT04335123, NCT04312009, NCT04311177 and NCT04340557). While a Chinese retrospective study of 1,128 adults suffering from hypertension and COVID-19 has concluded that use of both ACEIs and ARBs was associated with a lower risk of all-cause mortality compared to COVID-19 patients not using these medications [45], other reviews of the available clinical evidence do not agree [46].

The Chinese herbal medicine **glycyrrhizin** (Figure 6), a glycosylated saponin comprised of one molecule of glycyrrhetic acid and two molecules of glucuronic acid [47] found in the roots of Chinese liquorice *Glycyrrhiza uralensis* [48], has been predicted to bind ACE2 in a number of separate *in silico* studies. Chen and Du predicted glycyrrhizin to bind ACE2 with a binding energy of -9 kcal/mol and interact with residues R559, Q388, R393 and D30 [48], while separate work by Cinatl *et al.* found glycyrrhizin to have a high SI against SARS-CoV strains FFM-1 and FFM-2 *in vitro* during and after virus adsorption (SI >67 in Vero cells; EC₅₀ = 300 µg/mL, CC₅₀ = >20,000 µg/mL) [50]. The double ammonium salt of the compound, diammonium glycyrrhizinate, is currently being studied in two small-scale clinical trials against COVID-19 in China (ChiCTR2000029768 and ChiCTR2000030490).

2.3. Endosome-Targeting Drugs

Chloroquine (Aralen®; Figure 7), an antimalarial drug, has been identified as a promising small-molecule therapy for SARS-CoV-2 in a number of recent *in vitro* studies [51-53]; Wang and colleagues report that it has a high SI against SARS-CoV-2 *in vitro* (SI >88.50 in Vero E6 cells; EC₅₀ = 1.13 µM, CC₅₀ = >100 µM, MOI 0.05) [53], although it is known to induce life-threatening cardiac toxicity on rare occasions [54]. Chloroquine and its analogues possess tertiary amine functional groups and are thus weakly basic; the neutral, freebase forms can diffuse across membranes into acidic cytoplasmic organelles such as endosomes, whereupon they become protonated and unable to diffuse out [55, 56]. Concentration of chloroquine within endosomes in this manner increases the pH within the endosome [55, 56], blocking the pH-dependent fusion of the viral and endosome membranes that leads to release of viral genetic material within the host cell [57]. This mode of action is well-documented in a wide variety of different viruses [56-59], though additional modes of action have also been reported/predicted in SARS-CoV-2 [57, 60]. To further evaluate chloroquine as a treatment for COVID-19, a number of phase 2, 3 and 4 clinical trials in countries including China (NCT04319900, ChiCTR2000029741, ChiCTR2000029609, ChiCTR2000029542, ChiCTR2000031204, ChiCTR2000029975, ChiCTR2000029988, ChiCTR2000029939, ChiCTR2000030054, ChiCTR2000029899 and ChiCTR2000029898), Israel (NCT04333628), Poland (NCT04331600), Greece (NCT04344951), Vietnam (NCT04328493), France (NCT04333914), the US, Australia, Ireland, South Africa (NCT04333732), the UK (NCT04303507), Brazil (NCT04323527 and NCT04342650) and Canada (NCT04324463) are either planned, recruiting or currently active; of note is a French 273-person phase 2 trial for COVID-19 patients also suffering from advanced or metastatic cancer (NCT04333914).

Hydroxychloroquine (Plaquenil®; Figure 7), an analogue of chloroquine with similar promise against SARS-CoV-2 *in vitro* (SI = 61.45 in Vero E6 cells; EC₅₀ = 4.06 µM, CC₅₀ = 249.50 µM, MOI 0.02) [52], as well as associated drawbacks [54], is also the subject of a number of planned or active phase 1-4 clinical trials worldwide. These include studies in Canada (NCT04329611, NCT04308668 and NCT04321993), the US (NCT04329832, NCT04334512, NCT04329923, NCT04334382, NCT04333225, NCT04335084, NCT04336332, NCT04318444, NCT04328961, NCT04334148, NCT04335552, NCT04334967, NCT04332991, NCT04333654, NCT04328467, NCT04308668, NCT04328012, NCT04345692, NCT04341441, NCT04345653, NCT04343677 and NCT04342169), Singapore (NCT04342156), France (NCT04328285, NCT04325893 and NCT04344379), Germany (NCT04342221 and NCT04340544), Spain

(NCT04331834 and NCT04330495), Israel (NCT04323631), Brazil (NCT04329572, NCT04321278 and NCT04322123), Mexico (NCT04315896, NCT04318015 and NCT04340349), Pakistan (NCT04328272), South Korea (NCT04330144 and NCT04307693), China (NCT04261517, ChiCTR2000030054, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029803 and ChiCTR2000029559), Norway (NCT04321616 and NCT04316377), Denmark (NCT04322396), Austria (NCT04336748), Turkey (NCT04326725) and Iran (NCT04343768). Of note are two large scale, multinational trials assessing the utility of both chloroquine and hydroxychloroquine as prophylactic therapies for frontline healthcare workers (NCT04333732 and NCT04303507); other, smaller studies investigating both pre-exposure (NCT04328467, NCT04333225, NCT04328285, NCT04331834, NCT04318015, NCT04336748 and NCT04343677) and post-exposure (NCT04318444, NCT04330144, NCT04308668, NCT04322396, NCT04330495, NCT04326725, NCT04342156 and NCT04343677) prophylaxis on both healthcare workers and the general population are also being conducted in multiple countries. Combination with the macrolide antibiotic **azithromycin** (Zithromax®), another drug observed to have a high SI against SARS-CoV-2 *in vitro* (SI >19 in Vero E6 cells; EC₅₀ = 2.12 µM, CC₅₀ = >40 µM, MOI 0.002) [38], is also being assessed. Trials evaluating azithromycin either as a monotherapy (NCT04332107 and NCT04344379) or in combination with chloroquine or hydroxychloroquine (NCT04324463, NCT04329832, NCT04334512, NCT04334382, NCT04329572, NCT04336332, NCT04328272, NCT04335552, NCT04322396, NCT04321278, NCT04322123, NCT04339816, NCT04341727, NCT04341207, NCT04344444, NCT04338698 and NCT04344457) as well as other drugs (NCT04339426 and NCT04338698) are being initiated worldwide. Preliminary results appear mixed; while there are reports that suggest hydroxychloroquine monotherapy is associated with an increase in COVID-19 patient survival when started in the early stages of the disease [61], a meta-analysis of 11 clinical studies with a total of 2,354 patients receiving hydroxychloroquine does not support this conclusion [62].

2.4. Host Protease Inhibitors

Camostat mesylate (Foipan®; Figure 8), a serine protease inhibitor, is another possible treatment option. Approved for clinical use in Japan since the 1990s for treating chronic pancreatitis and postoperative reflux esophagitis [63], it has a high SI *in vitro* (SI >62 in MDCK cells; EC₅₀ = 3.2 µg/mL, CC₅₀ = >200 µg/mL) [64] and is active against both SARS-CoV [9, 65] – Zhou *et al.* found it conferred a 60% survival rate on mice injected with the virus [66] – and SARS-CoV-2 [67]. In the case of the latter, camostat mesylate blocks cellular entry *via* inhibition of the TMPRSS2 protease; Hoffmann *et al.* found that pre-treatment of Caco-2 cells with the

drug reduced SARS-CoV-2 virus entry by ~90% relative to untreated control cells *in vitro* [67]. Combination of camostat mesylate with **aloxistatin** (E-64d; Figure 8), a non-specific cysteine protease inhibitor first isolated by scientists at Taisho Pharmaceutical [68] and a known inhibitor of cathepsin B and cathepsin L [67], may be advantageous [65]; Hoffmann *et al.* report that this combination caused full inhibition of SARS-CoV-2 entry into Caco-2 cells, improving on camostat mesylate alone [67]. Clinical trials evaluating camostat mesylate alone or in combination with other drugs for treatment of COVID-19 patients are currently being organised in the US (NCT04353284, NCT04435015 and NCT04374019), Denmark (NCT04321096), Germany (NCT04338906) and Israel (NCT04355052).

3. VIRAL REPLICATION INHIBITORS

3.1. RNA-Dependent RNA Polymerase Inhibitors

Favipiravir (Avigan®; Figure 9) is a nucleoside analogue and pyrazinecarboxamide derivative developed by Toyama Chemical [69]. The active form of the drug, favipiravir ribofuranosyl-5'-triphosphate, is generated *via* intracellular phosphoribosylation [70]. Favipiravir has been clinically approved in Japan for the treatment of influenza virus infections that are resistant to other classes of antivirals. Despite a low SI against SARS-CoV-2 *in vitro* (SI >6.46 in Vero E6 cells; EC₅₀ = 61.88 µM, CC₅₀ = >400 µM, MOI 0.05) [53], favipiravir is currently being evaluated in a number of clinical trials in COVID-19 patients. In China, favipiravir has recently been trialled in 80 confirmed COVID-19 patients, 35 of whom received favipiravir for 14 days while the rest received a placebo. An initial report concluded that patients receiving favipiravir showed a substantially shorter viral clearance time and improved infection progression [71], though at the time of writing this article has been temporarily withdrawn [72]. Further trials in the UK (NCT04373733), Italy (NCT04336904), Thailand (NCT04303299), the US (NCT04358549 and NCT04346628), Canada (NCT04448119), Iran (NCT04359615 and NCT04376814), Bangladesh (NCT04402203), Russia (NCT04434248), Egypt (NCT04349241 and NCT04351295), Turkey (NCT04411433), Bahrain (NCT04387760), Saudi Arabia (NCT04392973), Germany, Romania (NCT04425460) and China (NCT04333589, NCT04310228, NCT04319900, ChiCTR2000029600, ChiCTR2000030113, ChiCTR2000029548, ChiCTR2000029544 and ChiCTR2000030254) assessing the utility of favipiravir either as a monotherapy or in combination with other biologic or small-molecule therapies appear to be in various stages of progression.

Ribavirin (Copegus®; Figure 9) was first synthesised in 1972 and is a guanosine analogue broad-spectrum antiviral agent indicated to treat hepatitis C and E, Lassa, Hanta and respiratory syncytial viruses [73]. The active triphosphate form of the drug is generated intracellularly [74] and inhibits viral RNA-dependant RNA polymerase as well as mRNA capping, thus blocking RNA synthesis and consequently viral replication [73]. The inhibitory effects of ribavirin on SARS-CoV *in vitro* appear to vary between different cell lines; although it showed potent inhibitory activity in MA104 (African green monkey kidney cell line; EC₅₀ 9.4 ± 4.1 µg/mL), PK-15 (pig kidney cell line; EC₅₀ 2.2 ± 0.8 µg/mL), Caco-2 (human colon carcinoma cell line; EC₅₀ 7.3 ± 3.5 µg/mL), CL14 (human colon carcinoma cell line; EC₅₀ 8.2 ± 4.2 µg/mL) and HPEK (human primary epithelial kidney cell line; EC₅₀ 5.2 ± 2.9 µg/mL) cells, no observable inhibition was found in Vero cells (African green monkey kidney cell line; EC₅₀ >1,000 µg/mL) [75] and this may explain the low SI observed for SARS-CoV-2 by Wang and colleagues (SI >3.65 in Vero E6 cells; EC₅₀ = 109.5 µM, CC₅₀ = >400 µM, MOI 0.05) [53]. Recruitment is currently underway in China for a number of clinical studies involving co-administration of ribavirin, lopinavir/ritonavir and/or various interferons to treat COVID-19 (NCT04276688, ChiCTR2000029387 and ChiCTR2000030922) while other trials in Egypt (NCT04392427) and Bangladesh (NCT04402203) are planned or recruiting patients. Of note is a Canadian 50-person phase 1 trial evaluating different doses of an inhaled solution of ribavirin (Virazole®) in COVID-19 patients (NCT04356677).

Remdesivir (GS-5734™; Figure 9) is a broad-spectrum nucleoside analogue originally developed by Gilead Sciences to treat the Ebola virus [76]. It is the monophosphoramidate precursor of the adenosine-based nucleoside analogue GS-441524 [77] and is converted to its active triphosphate form intracellularly [74] where it inhibits viral RNA-dependent RNA polymerase [78]. Wang *et al.* report a high SI for remdesivir against SARS-CoV-2 (SI >129.87 in Vero E6 cells; EC₅₀ = 0.77 µM, CC₅₀ = >100 µM, MOI 0.05) [53]. In response to its potential, both Gilead Sciences and the US Army Medical Research and Development Command have offered expanded access to remdesivir for COVID-19 patients (NCT04323761 and NCT04302766). Six different phase 3 clinical trials evaluating remdesivir in up to 3,100 COVID-19 patients were initiated as of early April 2020 (NCT04292899, NCT04292730, NCT04252664, NCT04315948, NCT04280705 and NCT04257656), of which two are recruiting participants and two are active at the time of writing. Preliminary data from one of the aforementioned studies shows statistically improved time to recovery *versus* placebo [79], though similar data from another trial does not support this conclusion [80]. As of the 1st of May 2020, the FDA

has granted remdesivir emergency use authorisation for the treatment of COVID-19 in hospitalised patients with severe disease [81].

3.2. Main Protease (M^{pro}) Inhibitors

Lopinavir/ritonavir (Kaletra®; Figure 10) is an antiretroviral combination medication developed by Abbott Laboratories for the treatment and prevention of HIV and AIDS. The combination has previously received interest for treatment of coronavirus infections (NCT00578825 and NCT02845843). Lopinavir (SI = 12.99 in Vero E6 cells; EC_{50} = 5.73 μ M, CC_{50} = 74.44 μ M, MOI 0.01) has been reported to have a higher SI than ritonavir (SI = 8.59 in Vero E6 cells; EC_{50} = 8.63 μ M, CC_{50} = 74.11 μ M, MOI 0.01) [82]. As of early March 2020, current license holders AbbVie Inc. have offered expanded access to lopinavir/ritonavir for the treatment of COVID-19 patients [83]. A number of phase 2-4 clinical trials of the combination therapy in both prophylactic and interventional capacities have been organised in the US (NCT04328012), France (NCT04328285), Canada (NCT04321993, NCT04330690 and NCT04321174), Iran (NCT04331470 and NCT04343768) and China (NCT04295551, NCT04276688, NCT04252885, NCT04261907, ChiCTR2000029741, ChiCTR2000029548, ChiCTR2000029541, ChiCTR2000029468, ChiCTR2000029387, ChiCTR2000029308, ChiCTR2000030187 and ChiCTR2000029539). However, preliminary results from a 160-person Chinese study indicate that there are no benefits to lopinavir/ritonavir treatment of COVID-19 patients beyond those of standard hospital care (NCT04261907) [84].

In silico modelling conducted by Huang and colleagues has predicted that a number of Chinese herbal medicine ingredients might be capable of inhibiting the SARS-CoV-2 M^{pro} enzyme, including **quercetin** (a bitter-tasting flavonol found in a variety of fruit and vegetables [85]; -5.6 kcal/mol [86]) and **baicalin** (a flavone glucuronide found in the roots of Chinese skullcap *Scutellaria baicalensis* [87]; -6.4 kcal/mol [86]) (Figure 11). Both compounds have previously been investigated for use in treating infections of SARS-CoV; IC_{50} values reported for quercetin against SARS-CoV M^{pro} range from $23.8 \pm 1.9 \mu$ M [88] to $73 \pm 4 \mu$ M [89], while Chen *et al.* observed a low SI for baicalin against ten strains of SARS-CoV *in vitro* after 48 hours (SI >4 in FRhK-4 cells; EC_{50} = 12.5-25 μ M, CC_{50} = >100 μ M) [90]. A 50-person trial evaluating quercetin as both a COVID-19 treatment and prophylactic is currently recruiting in Turkey (NCT04377789).

4. IMMUNE RESPONSE MODULATORS

While inhibition of the SARS-CoV-2 infection cycle is undoubtedly a promising means of controlling the current pandemic, no review of small-molecule therapies here would be complete without also considering therapies for managing the associated disease COVID-19. Indeed, the major cause of death in clinical cases of SARS-CoV-2 infection is ARDS [28, 29], triggered by virus-mediated ACE2 downregulation disrupting the renin-angiotensin system, inducing a cytokine storm and leading to a host inflammatory response (NCT04344041) [19]. A number of different anti-inflammatory, immune modulatory and other drugs are currently being trialled with a view to preventing ARDS in severe cases of COVID-19 and thus reducing the associated mortality rate.

4.1. Corticosteroids

A recent publication by Russell and colleagues has recommended that **corticosteroids**, widely used to treat patients during the SARS-CoV and MERS-CoV outbreaks, should not be used in the case of COVID-19-related pneumonia, lung injury or septic shock except in clinical trial settings [32]. However, this advice is disputed in a subsequent publication by Zhao *et al.* which instead advises cautious use [33]. Despite the controversy surrounding their use, a number of different corticosteroids including **dexamethasone** (Dextenza®; NCT04381936, NCT04325061, NCT04347980, NCT04395105, NCT04360876, NCT04327401, NCT04445506, NCT04344730 and ChiCTR2000029656), **ciclesonide** (Alvesco®; NCT04330586, NCT04377711, NCT04435795 and NCT04381364), **budesonide** (Pulmicort®; NCT04331470, NCT04361474, NCT04416399, NCT04355637, NCT04193878 and NCT04331054), **prednisone** (Deltasone®; NCT04344288 and NCT04359511) and **methylprednisolone** (Medrol®; NCT03852537, NCT04329650, NCT04377503, NCT04345445, NCT04438980, NCT04355247, NCT04374071, NCT04273321, NCT04263402, NCT04244591, NCT04323592, NCT04343729 and NCT04341038) (Figure 12) are currently being trialled in COVID-19 patients across the world. Initial results from a 12,000-person UK randomised study evaluating dexamethasone in COVID-19 patients, with 2,104 patients receiving 6 mg of dexamethasone once daily for ten days *versus* 4,321 patients receiving standard-of-care, indicate that it is effective in reducing mortality rates in COVID-19 patients requiring ventilation (28-day mortality rate reduced by one third) or supplemental oxygen treatment (28-day mortality rate reduced by one fifth) [91].

4.2. Cytokine Production Inhibitors

A number of cytokines have been reported to be involved in the human immune response to COVID-19, including IL-1, IL-2, IL4, IL-6, IL-10, IL-12, IL-13, IL-17, GCSF, MCSF, IP-10, MCP-1, MIP-1 α , HGF, IFN- γ and TNF- α (NCT04334044), and thus inhibitors of their production may prevent ARDS [92]. **Colchicine** (Colcrys®; Figure 13), an anti-inflammatory approved for the management of acute gout that targets the NLRP3 inflammasome to reduce the release of cytokines IL-1 β and IL-6 [93], is currently the subject of various phase 2 and 3 clinical trials for COVID-19-associated ARDS in Italy (NCT04322565), Canada (NCT04322682 and NCT04328480), Greece (NCT04326790) and Argentina (NCT04328480). **Baricitinib** (Olumiant™), **ruxolitinib** (Jakafi®) and **tofacitinib** (Xeljanz®) (Figure 13), inhibitors of the Janus kinase family of enzymes that mediate an inhibition of cytokine signalling [94], are due to be trialled in different studies in Italy (NCT04320277 and NCT04332042), Germany (NCT04338958), Canada (NCT04331665), Mexico (NCT04334044), China (ChiCTR2000029580) and the US (NCT04340232), though their use is still the subject of debate [95-97]. **Deferoxamine** (Desferal®; Figure 13), an iron and aluminium chelator, has previously been observed to block IL-6 production in a porcine sepsis inflammatory response syndrome model [98] and intravenous deferoxamine therapy is currently the subject of a 50-person phase 1 trial for treatment of COVID-19 in Iran (NCT04333550). **Escin** (Reparil®), a mixture of saponins found in the horse chestnut *Aesculus hippocastanum* thought to suppress the release of pro-inflammatory cytokines via a reduction of high mobility group box 1 (HMGB1) secretion [99], is being evaluated in separate COVID-19 clinical trials in Italy (NCT04322344) and China (ChiCTR2000029742).

4.3. Cardioprotective Medications

While most infections of SARS-CoV-2 have resulted in COVID-19 as a mild respiratory illness, a subgroup of patients experience a severe illness and require invasive cardio-respiratory support in an ICU setting. There is evidence that severe COVID-19 requiring ICU treatment is correlated with incidence of acute cardiac injury; however, the details surrounding the latter are as yet poorly understood. A study by Imperial College London is seeking to investigate this further in a 3,170-person clinical trial assessing the utility of cardioprotective medicines **aspirin**, **clopidogrel** (Plavix®), **rivaroxaban** (Xarelto®), **atorvastatin** (Lipitor®) and **omeprazole** (Prilosec®) (Figure 14) in preventing cardiac complications in COVID-19 patients. The trial is currently at the recruitment stage (NCT04333407).

4.4. Other Drugs

Other drugs being investigated for their anti-inflammatory properties (Figure 15) include the nonsteroidal anti-inflammatory drugs **ibuprofen** (Advil®), **naproxen** (Aleve®), **aspirin** and **indometacin** (Indocid™) in clinical studies in the UK (NCT04334629), France (NCT04325633), Pakistan (NCT04343001) and the US (NCT04344457), respectively; the vasodilator **sildenafil** (Viagra®; NCT04304313); **thalidomide** (Thalomid®; NCT04273581 and NCT04273529); the sphingosine-1-phosphate receptor modulator **fingolimod** (Gilenya®; NCT04280588); and antifibrotic drug **pirfenidone** (Esbriet®; NCT04282902, ChiCTR2000031138 and ChiCTR2000030892).

Vitamin C (ascorbic acid; Figure 15) has previously been observed to exert effects on the immune system supporting adaptive and innate immunity [100]. Individuals suffering from acute respiratory infections such as pneumonia have reduced vitamin C plasma concentrations when compared to control subjects [101]; a trial by Mochalkin and co-workers using vitamin C at doses of 0.25-0.8 g/day in pneumonia patients reduced average duration of hospitalisation by 19% relative to a control group, while a higher dose of 0.5-1.6 g/day reduced average duration of hospitalisation by 36% [102]. A number of other studies have indicated a role for vitamin C in providing resistance to coronavirus infections [103, 104]. It is currently being studied as part of multiple COVID-19 clinical trials in the US (NCT04328961, NCT04344184 and NCT04342728), Turkey (NCT04337281), Italy (NCT04323514), Canada (NCT03680274) and China (ChiCTR2000029768). **Vitamin D** is also due to be studied as an immune modulatory agent for the treatment of COVID-19 patients in separate trials in France (NCT04344041) and Spain (NCT04334005).

5. CONCLUSION AND FUTURE PERSPECTIVE

The COVID-19 pandemic is currently predicted to cost the global economy up to and in excess of 1 trillion USD [105]. In recent years, a number of different commentators have opined that the world is ill-prepared to deal with the next pandemic [106-108] and it would appear their collective fears were well-founded. The current pandemic thus highlights the importance of strong anti-infective research and therapeutics development programmes. While research into therapies to tackle SARS-CoV-2 is a short term priority, governments worldwide must also take a longer term view. Specifically, countries need to come together to develop an investment and reimbursement model to encourage anti-infectives research and development so that humanity is better prepared to tackle future infectious disease pandemics.

442

443 Fortunately, global research into small-molecule therapies for SARS-CoV-2 and COVID-19 is progressing at an
 444 unprecedented rate. The fact that there are over 200 clinical trials currently being conducted worldwide into
 445 different small-molecule therapies is an incredible feat of organisation given the short amount of time the
 446 SARS-CoV-2 virus has been known to science and the medical personnel and scientists responsible are rightly
 447 deserving of high praise. However, it is essential that these clinical studies remain scientifically rigorous; the
 448 overwhelming demand for any form of treatment must not be allowed to detract from the quality of data
 449 gathered nor the validity of conclusions reported. Recent instances of trial design and protocol controversy [109-
 450 111], trial suspension with minimal explanation (NCT04252664 and NCT04257656) and improper
 451 dissemination of preliminary trial findings [112] cannot be allowed to become commonplace. Only when the
 452 randomised trials currently in progress begin to report properly vetted findings can conclusions be drawn.

453

454 Once effective small-molecule treatments for COVID-19 are identified, it is important that COVID-19 patients
 455 be started on courses of the drug(s) as soon as possible. This will depend on the widespread use of rapid
 456 diagnostic tests to determine whether a patient is infected with SARS-CoV-2. To this end, worldwide
 457 development of a variety of diagnostic approaches is proceeding in parallel with the aforementioned efforts to
 458 identify small-molecule treatments [113-121]. Widespread and expeditious testing is thought to have been key
 459 to South Korea's low COVID-19-related mortality rate [122] – approximately 2.2% as of the 28th of June 2020
 460 [2] – and increasing levels of testing worldwide in recent months are therefore encouraging [123].

461

462 If a previously experimental drug such as Gilead's remdesivir proves to be useful in treating COVID-19
 463 patients, the next hurdle to overcome will be the lack of an established unit price. Gilead has sought to downplay
 464 remdesivir's commercial potential throughout the current pandemic, even providing its existing stock of 1.5
 465 million doses free of charge [124], but this scenario cannot continue indefinitely. In deciding on a reasonable
 466 price, the promise of a faster return to normalcy must be weighed against the current plight of global economies
 467 and the limited funds available for population-wide distribution. Yet the production costs associated with
 468 remdesivir could prohibit its widespread use; the Institute for Clinical and Economic Review (ICER) estimates
 469 that a 10-day course of remdesivir costs 10 USD to produce [125], placing it far above many drugs on the WHO
 470 Essential Medicines List [126] as well as a number of other drugs being trialled against SARS-CoV-2 [127].
 471 With the market price of remdesivir all but guaranteed to exceed the production figure – the ICER estimate a

price of up to 4,500 USD as cost-effective [125] – it remains to be seen if use of remdesivir will be feasible on a global scale.

A decisive factor in determining how long a small-molecule therapy for SARS-CoV-2 will take to reach the clinic may well be the degree to which scientists of different nationalities, disciplines and industry sectors are able to cooperate. The field is where it currently is largely thanks to the effective organisation and execution of a number of large collaborative projects [7, 128-130]; with countries around the world imposing lockdown measures in a bid to ease the pressure on struggling healthcare systems, innovative schemes facilitating such large-scale collaborations are now more important than ever. PostEra, a US/UK startup specialising in machine learning-powered medicinal chemistry, is leading a crowdsourced initiative to harness the data generated by the XChem fragment screening experiment at the Diamond Light Source to create novel M^{pro} inhibitors by asking scientists around the world to analyse the data and suggest combinations of hit fragments for synthesis and *in vitro* testing [131]. The *Coronavirus Tech Handbook*, a crowdsourced resource library based around COVID-19, has been established by faculty members of Newspeak House in the UK to bring together expert contributors in a range of different disciplines to help tackle the pandemic [132]. Time will tell if these innovative approaches to drug design and research prove fruitful.

488 ***Abbreviations***

489	3C ^{Pro}	3C Protease
490	ACE2	Angiotensin-Converting Enzyme 2
491	ACEI	Angiotensin Converting Enzyme Inhibitors
492	ARB	Angiotensin II Receptor Blockers
493	ARDS	Acute Respiratory Distress Syndrome
494	CC ₅₀	Half Maximal Cytotoxic Concentration
495	ChiCTR	Chinese Clinical Trial Registry
496	COVID-19	Coronavirus Disease 2019
497	CRS	Cytokine Release Syndrome
498	E	Envelope
499	EC ₅₀	Half Maximal Effective Concentration
500	HMGB1	High Mobility Group Box 1
501	HPEK	Human Primary Epithelial Kidney cell line
502	ICER	Institute for Clinical and Economic Review
503	IDLH	Immediately Dangerous To Life or Health
504	M	Membrane
505	MERS-CoV	Middle East Respiratory Syndrome Coronavirus
506	MOI	Multiplicity Of Infection
507	M ^{Pro} /3CL ^{Pro}	Coronavirus Main Protease
508	N	Nucleocapsid
509	NCTC	National Clinical Trials Consortium
510	NIOSH	National Institute for Occupational Safety and Health
511	ORF	Open Reading Frame
512	PDB	Protein Data Bank
513	PL ^{Pro}	Papain-Like Protease
514	RBD	Receptor Binding Domain
515	S	Spike
516	SARS-CoV	Severe Acute Respiratory Syndrome Coronavirus
517	SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2

518	SI	Selectivity Index
519	TMPRSS2	Transmembrane Protease Serine 2
520	US	United States of America
521	WHO	World Health Organisation

522

523 *Contributions*

524 All authors researched data for the article, made substantial contributions to discussions of the content, wrote the
525 article and reviewed and edited the manuscript before submission.

526

527 *Conflict of Interest Declarations*

528 None to declare.

529

530 *Acknowledgements*

531 We acknowledge the Medical Research Council, Biotechnology and Biological Sciences Research Council,
532 Emergent BioSolutions, King's College London and the Commonwealth Scholarship Council for funding the
533 research activities of the authors of this manuscript. No funding was provided specifically for this work and the
534 authors volunteered in response to the COVID-19 pandemic.

6. REFERENCES

- [1] Cascella, M.; Rajnik, M.; Cuomo, A.; Dulebohn, S.C.; Di Napoli, R. *Features, Evaluation and Treatment Coronavirus (COVID-19)*; StatPearls Publishing LLC: Treasure Island (FL), **2020**.
- [2] Worldometer COVID-19 Coronavirus Pandemic. <https://www.worldometers.info/coronavirus/> (Accessed April 22, 2020).
- [3] Weiss, S.R.; Leibowitz, J.L. Coronavirus pathogenesis. *Adv Virus Res*, **2011**, *81*, 85-164.
- [4] Cui, J.; Li, F.; Shi, Z.L. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol*, **2019**, *17*(3), 181-192.
- [5] Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*, **2020**, *382*(8), 727-733.
- [6] Tang, B.; Bragazzi, N.L.; Li, Q.; Tang, S.; Xiao, Y.; Wu, J. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCoV). *Infect Dis Model*, **2020**, *5*, 248-255.
- [7] Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. *Science*, **2020**.
- [8] Kim, Y.; Jedrzejczak, R.; Maltseva, N.I.; Endres, M.; Godzik, A.; Michalska, K.; Joachimiak, A. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. *bioRxiv*, **2020**, 2020.2003.2002.968388.
- [9] Simmons, G.; Zmora, P.; Gierer, S.; Heurich, A.; Pohlmann, S. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. *Antiviral Res*, **2013**, *100*(3), 605-614.
- [10] Shereen, M.A.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res*, **2020**, *24*, 91-98.
- [11] Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Velesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*, **2020**.
- [12] Morse, J.S.; Lalonde, T.; Xu, S.; Liu, W.R. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. *Chembiochem*, **2020**, *21*(5), 730-738.
- [13] Pyrc, K.; Bosch, B.J.; Berkhout, B.; Jebbink, M.F.; Dijkman, R.; Rottier, P.; van der Hoek, L. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. *Antimicrob Agents Chemother*, **2006**, *50*(6), 2000-2008.
- [14] Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.G.; Decroly, E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res*, **2020**, *176*, 104742.
- [15] Lim, Y.X.; Ng, Y.L.; Tam, J.P.; Liu, D.X. Human Coronaviruses: A Review of Virus-Host Interactions. *Diseases*, **2016**, *4*(3).
- [16] Ziebuhr, J.; Snijder, E.J.; Gorbalenya, A.E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. *J Gen Virol*, **2000**, *81*, 853-879.
- [17] Gorbalenya, A.E.; Donchenko, A.P.; Blinov, V.M.; Koonin, E.V. Cysteine proteases of positive strand RNA viruses and chymotrypsin-like serine proteases. A distinct protein superfamily with a common structural fold. *FEBS Lett*, **1989**, *243*(2), 103-114.
- [18] Brockway, S.M.; Clay, C.T.; Lu, X.T.; Denison, M.R. Characterization of the expression, intracellular localization, and replication complex association of the putative mouse hepatitis virus RNA-dependent RNA polymerase. *J Virol*, **2003**, *77*(19), 10515-10527.
- [19] Shi, Y.; Wang, Y.; Shao, C.; Huang, J.; Gan, J.; Huang, X.; Bucci, E.; Piacentini, M.; Ippolito, G.; Melino, G. COVID-19 infection: the perspectives on immune responses. *Cell Death Differ*, **2020**.
- [20] Li, G.; De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nat Rev Drug Discov*, **2020**, *19*(3), 149-150.

- 585 [21] Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K.Y.;
586 Wang, Q.; Zhou, H.; Yan, J.; Qi, J. Structural and Functional Basis of SARS-CoV-2 Entry by Using
587 Human ACE2. *Cell*, **2020**.
- 588 [22] Pillaiyar, T.; Manickam, M.; Namasivayam, V.; Hayashi, Y.; Jung, S.H. An Overview of Severe
589 Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors:
590 Peptidomimetics and Small Molecule Chemotherapy. *J Med Chem*, **2016**, 59(14), 6595-6628.
- 591 [23] Tanner, J.A.; Zheng, B.J.; Zhou, J.; Watt, R.M.; Jiang, J.Q.; Wong, K.L.; Lin, Y.P.; Lu, L.Y.; He, M.L.;
592 Kung, H.F.; Kesel, A.J.; Huang, J.D. The adamantane-derived bananins are potent inhibitors of
593 the helicase activities and replication of SARS coronavirus. *Chem Biol*, **2005**, 12(3), 303-311.
- 594 [24] Beck, B.R.; Shin, B.; Choi, Y.; Park, S.; Kang, K. Predicting commercially available antiviral drugs
595 that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep
596 learning model. *Comput Struct Biotechnol J*, **2020**.
- 597 [25] Littler, D.R.; Gully, B.S.; Colson, R.N.; Rossjohn, J. Crystal structure of the SARS-CoV-2 non-
598 structural protein 9, Nsp9. *bioRxiv*, **2020**, 2020.2003.2028.013920.
- 599 [26] Laborda, P.; Wang, S.Y.; Voglmeir, J. Influenza Neuraminidase Inhibitors: Synthetic
600 Approaches, Derivatives and Biological Activity. *Molecules*, **2016**, 21(11).
- 601 [27] Liao, Y.; Tam, J.P.; Liu, D.X. Viroporin activity of SARS-CoV E protein. *Adv Exp Med Biol*, **2006**,
602 581, 199-202.
- 603 [28] Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.;
604 Zhao, Y.; Li, Y.; Wang, X.; Peng, Z. Clinical Characteristics of 138 Hospitalized Patients With
605 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*, **2020**, 323(11), 1061-
606 1069.
- 607 [29] Chen, T.; Wu, D.; Chen, H.; Yan, W.; Yang, D.; Chen, G.; Ma, K.; Xu, D.; Yu, H.; Wang, H.; Wang,
608 T.; Guo, W.; Chen, J.; Ding, C.; Zhang, X.; Huang, J.; Han, M.; Li, S.; Luo, X.; Zhao, J.; Ning, Q.
609 Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective
610 study. *BMJ*, **2020**, 368, m1091.
- 611 [30] Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. Molecular immune pathogenesis and diagnosis of
612 COVID-19. *Journal of Pharmaceutical Analysis*, **2020**.
- 613 [31] Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.;
614 Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.;
615 Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with
616 2019 novel coronavirus in Wuhan, China. *Lancet*, **2020**, 395(10223), 497-506.
- 617 [32] Russell, C.D.; Millar, J.E.; Baillie, J.K. Clinical evidence does not support corticosteroid
618 treatment for 2019-nCoV lung injury. *The Lancet*, **2020**, 395(10223), 473-475.
- 619 [33] Zhao, J.; Hu, Y.; Du, R.; Chen, Z.; Jin, Y.; Zhou, M.; Zhang, J.; Qu, J.; Cao, B. Expert consensus on
620 the use of corticosteroid in patients with 2019-nCoV pneumonia. *Zhonghua jie he he hu xi za*
621 *zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases*,
622 **2020**, 43(3), 183-184.
- 623 [34] Zhang, J.; Zhou, L.; Yang, Y.; Peng, W.; Wang, W.; Chen, X. Therapeutic and triage strategies
624 for 2019 novel coronavirus disease in fever clinics. *Lancet Respir Med*, **2020**, 8(3), e11-e12.
- 625 [35] Khamitov, R.A.; Loginova, S.; Shchukina, V.N.; Borisevich, S.V.; Maksimov, V.A.; Shuster, A.M.
626 [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute
627 respiratory syndrome in the cell cultures]. *Vopr Virusol*, **2008**, 53(4), 9-13.
- 628 [36] Wu, C.; Liu, Y.; Yang, Y.; Zhang, P.; Zhong, W.; Wang, Y.; Wang, Q.; Xu, Y.; Li, M.; Li, X.; Zheng,
629 M.; Chen, L.; Li, H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential
630 drugs by computational methods. *Acta Pharmaceutica Sinica B*, **2020**.
- 631 [37] Teissier, E.; Zandomenighi, G.; Loquet, A.; Lavillette, D.; Lavergne, J.P.; Montserret, R.; Cosset,
632 F.L.; Bockmann, A.; Meier, B.H.; Penin, F.; Pecheur, E.I. Mechanism of inhibition of enveloped
633 virus membrane fusion by the antiviral drug arbidol. *PLoS One*, **2011**, 6(1), e15874.

- [38] Touret, F.; Gilles, M.; Barral, K.; Nougairède, A.; Decroly, E.; de Lamballerie, X.; Coutard, B. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. *bioRxiv*, **2020**, 2020.2004.2003.023846.
- [39] Boriskin, Y.S.; Pecheur, E.I.; Polyak, S.J. Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. *Virology*, **2006**, 3, 56.
- [40] Brancato, V.; Peduto, A.; Wharton, S.; Martin, S.; More, V.; Di Mola, A.; Massa, A.; Perfetto, B.; Donnarumma, G.; Schiraldi, C.; Tufano, M.A.; de Rosa, M.; Filosa, R.; Hay, A. Design of inhibitors of influenza virus membrane fusion: synthesis, structure-activity relationship and in vitro antiviral activity of a novel indole series. *Antiviral Res*, **2013**, 99(2), 125-135.
- [41] Shi, L.; Xiong, H.; He, J.; Deng, H.; Li, Q.; Zhong, Q.; Hou, W.; Cheng, L.; Xiao, H.; Yang, Z. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. *Arch Virol*, **2007**, 152(8), 1447-1455.
- [42] Lian, N.; Xie, H.; Lin, S.; Huang, J.; Zhao, J.; Lin, Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. *Clin Microbiol Infect*, **2020**.
- [43] Akerstrom, S.; Gunalan, V.; Keng, C.T.; Tan, Y.J.; Mirazimi, A. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. *Virology*, **2009**, 395(1), 1-9.
- [44] NIOSH Nitric oxide. <https://www.cdc.gov/niosh/idlh/10102439.html> (Accessed May 19, 2020).
- [45] Zhang, P.; Zhu, L.; Cai, J.; Lei, F.; Qin, J.; Xie, J.; Zhao, Y.; Huang, X.; Lin, L.; Xia, M.; Chen, M.; Cheng, X.; Zhang, X.; Guo, D.; Peng, Y.; Ji, Y.-X.; Chen, J.; She, Z.-G.; Wang, Y.; Xu, Q.; Tan, R.; Wang, H.; Lin, J.; Luo, P.; Fu, S.; Cai, H.; Ye, P.; Xiao, B.; Mao, W.; Liu, L.; Yan, Y.; Liu, M.; Chen, M.; Zhang, X.-J.; Wang, X.; Touyz, R.M.; Xia, J.; Zhang, B.-H.; Huang, X.; Yuan, Y.; Rohit, L.; Liu, P.P.; Li, H. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circulation Research*, **2020**.
- [46] Rico-Mesa, J.S.; White, A.; Anderson, A.S. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. *Curr Cardiol Rep*, **2020**, 22(5), 31.
- [47] Kimura, M.; Watanabe, H.; Abo, T. Selective activation of extrathymic T cells in the liver by glycyrrhizin. *Biotherapy*, **1992**, 5(3), 167-176.
- [48] Chen, H.; Du, Q. Potential Natural Compounds for Preventing SARS-CoV-2 (2019-nCoV) Infection. *Preprints*, **2020**.
- [49] Takahashi, S.; Yoshiya, T.; Yoshizawa-Kumagaye, K.; Sugiyama, T. Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. *Biomedical Research*, **2015**, 36(3), 219-224.
- [50] Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. *The Lancet*, **2003**, 361(9374), 2045-2046.
- [51] Yao, X.; Ye, F.; Zhang, M.; Cui, C.; Huang, B.; Niu, P.; Liu, X.; Zhao, L.; Dong, E.; Song, C. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clinical Infectious Diseases*, **2020**.
- [52] Liu, J.; Cao, R.; Xu, M.; Wang, X.; Zhang, H.; Hu, H.; Li, Y.; Hu, Z.; Zhong, W.; Wang, M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery*, **2020**, 6(1), 1-4.
- [53] Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell research*, **2020**, 30(3), 269-271.
- [54] Frisk-Holmberg, M.; Bergqvist, Y.; Englund, U. Chloroquine intoxication. *British journal of clinical pharmacology*, **1983**, 15(4), 502.

- 685 [55] Al-Bari, M.A. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of
686 actions and toxic manifestations from malaria to multifarious diseases. *J Antimicrob*
687 *Chemother*, **2015**, 70(6), 1608-1621.
- 688 [56] Al-Bari, M.A.A. Targeting endosomal acidification by chloroquine analogs as a promising
689 strategy for the treatment of emerging viral diseases. *Pharmacol Res Perspect*, **2017**, 5(1),
690 e00293.
- 691 [57] Devaux, C.A.; Rolain, J.M.; Colson, P.; Raoult, D. New insights on the antiviral effects of
692 chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob Agents*, **2020**,
693 105938.
- 694 [58] Savarino, A.; Boelaert, J.R.; Cassone, A.; Majori, G.; Cauda, R. Effects of chloroquine on viral
695 infections: an old drug against today's diseases? *Lancet Infect Dis*, **2003**, 3(11), 722-727.
- 696 [59] Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah,
697 N.G.; Nichol, S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
698 *Virology Journal*, **2005**, 2(1), 69.
- 699 [60] Fantini, J.; Scala, C.D.; Chahinian, H.; Yahi, N. Structural and molecular modeling studies reveal
700 a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2
701 infection. *Int J Antimicrob Agents*, **2020**, 105960.
- 702 [61] Membrillo, F.J.; Ramírez-Olivencia, G.; Estébanez, M.; de Dios, B.; Herrero, M.D.; Mata, T.;
703 Borobia, A.M.; Gutiérrez, C.; Simón, M.; Ochoa, A.; Martínez, Y.; Aguirre, A.; Alcántara, F.D.A.;
704 Fernández-González, P.; López, E.; Valle, P.; Campos, S.; Navarro, M.; Ballester, L.E. Early
705 Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An
706 Observational Study. *Preprints*, **2020**, 2020050057.
- 707 [62] Chacko, J.; Brar, G.; Premkumar, R. Hydroxychloroquine in COVID-19: A systematic review and
708 meta-analysis. *medRxiv*, **2020**, 2020.2005.2014.20101774.
- 709 [63] Gibo, J.; Ito, T.; Kawabe, K.; Hisano, T.; Inoue, M.; Fujimori, N.; Oono, T.; Arita, Y.; Nawata, H.
710 Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic
711 stellate cells activity. *Lab Invest*, **2005**, 85(1), 75-89.
- 712 [64] Hosoya, M.; Shigeta, S.; Ishii, T.; Suzuki, H.; De Clercq, E. Comparative inhibitory effects of
713 various nucleoside and nonnucleoside analogues on replication of influenza virus types A and
714 B in vitro and in ovo. *J Infect Dis*, **1993**, 168(3), 641-646.
- 715 [65] Kawase, M.; Shirato, K.; van der Hoek, L.; Taguchi, F.; Matsuyama, S. Simultaneous treatment
716 of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents
717 severe acute respiratory syndrome coronavirus entry. *J Virol*, **2012**, 86(12), 6537-6545.
- 718 [66] Zhou, Y.; Vedantham, P.; Lu, K.; Agudelo, J.; Carrion, R., Jr.; Nunneley, J.W.; Barnard, D.;
719 Pohlmann, S.; McKerrow, J.H.; Renslo, A.R.; Simmons, G. Protease inhibitors targeting
720 coronavirus and filovirus entry. *Antiviral Res*, **2015**, 116, 76-84.
- 721 [67] Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Kruger, N.; Herrler, T.; Erichsen, S.; Schiergens,
722 T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; Muller, M.A.; Drosten, C.; Pohlmann, S. SARS-CoV-2 Cell
723 Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
724 *Cell*, **2020**.
- 725 [68] Hanada, K.; Tamai, M.; Yamagishi, M.; Ohmura, S.; Sawada, J.; Tanaka, I. Isolation and
726 Characterization of E-64, a New Thiol Protease Inhibitor. *Agricultural and Biological Chemistry*,
727 **1978**, 42(3), 523-528.
- 728 [69] Goldhill, D.H.; Te Velhuis, A.J.W.; Fletcher, R.A.; Langat, P.; Zambon, M.; Lackenby, A.; Barclay,
729 W.S. The mechanism of resistance to favipiravir in influenza. *Proc Natl Acad Sci U S A*, **2018**,
730 115(45), 11613-11618.
- 731 [70] Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral
732 RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci*, **2017**, 93(7), 449-463.
- 733 [71] Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y.; Shen, C.; Li,
734 X.; Peng, L.; Huang, D.; Zhang, J.; Zhang, S.; Wang, F.; Liu, J.; Chen, L.; Chen, S.; Wang, Z.; Zhang,

- Z.; Cao, R.; Zhong, W.; Liu, Y.; Liu, L. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering*, **2020**.
- [72] Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y.; Shen, C.; Li, X.; Peng, L.; Huang, D.; Zhang, J.; Zhang, S.; Wang, F.; Liu, J.; Chen, L.; Chen, S.; Wang, Z.; Zhang, Z.; Cao, R.; Zhong, W.; Liu, Y.; Liu, L. TEMPORARY REMOVAL: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering*, **2020**.
- [73] Totura, A.L.; Bavari, S. Broad-spectrum coronavirus antiviral drug discovery. *Expert Opin Drug Discov*, **2019**, 14(4), 397-412.
- [74] Gordon, C.J.; Tchesnokov, E.P.; Woolner, E.; Perry, J.K.; Feng, J.Y.; Porter, D.P.; Gotte, M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. *J Biol Chem*, **2020**, 295(20), 6785-6797.
- [75] Morgenstern, B.; Michaelis, M.; Baer, P.C.; Doerr, H.W.; Cinatl, J., Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. *Biochem Biophys Res Commun*, **2005**, 326(4), 905-908.
- [76] Warren, T.K.; Jordan, R.; Lo, M.K.; Ray, A.S.; Mackman, R.L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H.C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K.S.; Van Tongeren, S.A.; Garza, N.L.; Donnelly, G.; Shurtleff, A.C.; Retterer, C.J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B.P.; Grimes, E.; Welch, L.S.; Gomba, L.; Wilhelmsen, C.L.; Nichols, D.K.; Nuss, J.E.; Nagle, E.R.; Kugelman, J.R.; Palacios, G.; Doerffler, E.; Neville, S.; Carra, E.; Clarke, M.O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K.M.; Trancheva, I.; Feng, J.Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M.R.; Flint, M.; McMullan, L.K.; Chen, S.S.; Fearn, R.; Swaminathan, S.; Mayers, D.L.; Spiropoulou, C.F.; Lee, W.A.; Nichol, S.T.; Cihlar, T.; Bavari, S. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature*, **2016**, 531(7594), 381-385.
- [77] Agostini, M.L.; Andres, E.L.; Sims, A.C.; Graham, R.L.; Sheahan, T.P.; Lu, X.; Smith, E.C.; Case, J.B.; Feng, J.Y.; Jordan, R.; Ray, A.S.; Cihlar, T.; Siegel, D.; Mackman, R.L.; Clarke, M.O.; Baric, R.S.; Denison, M.R. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. *mBio*, **2018**, 9(2).
- [78] Sheahan, T.P.; Sims, A.C.; Graham, R.L.; Menachery, V.D.; Gralinski, L.E.; Case, J.B.; Leist, S.R.; Pyrc, K.; Feng, J.Y.; Trantcheva, I.; Bannister, R.; Park, Y.; Babusis, D.; Clarke, M.O.; Mackman, R.L.; Spahn, J.E.; Palmiotti, C.A.; Siegel, D.; Ray, A.S.; Cihlar, T.; Jordan, R.; Denison, M.R.; Baric, R.S. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med*, **2017**, 9(396).
- [79] NIH NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. <https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19> (Accessed May 19, 2020).
- [80] Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Cao, B.; Wang, C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*, **2020**, 395(10236), 1569-1578.
- [81] FDA Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment> (Accessed May 20, 2020).
- [82] Yamamoto, N.; Matsuyama, S.; Hoshino, T.; Yamamoto, N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. *bioRxiv*, **2020**, 2020.2004.2006.026476.

- 785 [83] Infante, A. AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in
786 Treating COVID-19. [https://news.abbvie.com/news/press-releases/abbvie-partnering-](https://news.abbvie.com/news/press-releases/abbvie-partnering-with-global-authorities-to-determine-efficacy-hiv-drug-in-treating-covid-19.htm)
787 [with-global-authorities-to-determine-efficacy-hiv-drug-in-treating-covid-19.htm](https://news.abbvie.com/news/press-releases/abbvie-partnering-with-global-authorities-to-determine-efficacy-hiv-drug-in-treating-covid-19.htm) (Accessed
788 April 11, 2020).
- 789 [84] Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.;
790 Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang,
791 H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.;
792 Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.;
793 Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.;
794 Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A
795 Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*, **2020**.
- 796 [85] Ay, M.; Charli, A.; Jin, H.; Anantharam, V.; Kanthasamy, A.; Kanthasamy, A.G. In *Nutraceuticals*.
797 Gupta, R.C., Ed.; Academic Press: Boston, **2016**, pp 447-452.
- 798 [86] Huang, F.; Li, Y.; Leung, E.L.; Liu, X.; Liu, K.; Wang, Q.; Lan, Y.; Li, X.; Yu, H.; Cui, L.; Luo, H.; Luo,
799 L. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-
800 19). *Pharmacol Res*, **2020**, *158*, 104929.
- 801 [87] Zhang, W.; Zhou, H.; Liu, Z.; Chen, X.; He, Y. In *Handbook of Pharmacogenomics and Stratified*
802 *Medicine*. Padmanabhan, S., Ed.; Academic Press: San Diego, **2014**, pp 999-1013.
- 803 [88] Ryu, Y.B.; Jeong, H.J.; Kim, J.H.; Kim, Y.M.; Park, J.Y.; Kim, D.; Nguyen, T.T.; Park, S.J.; Chang,
804 J.S.; Park, K.H.; Rho, M.C.; Lee, W.S. Biflavonoids from *Torreya nucifera* displaying SARS-CoV
805 3CL(pro) inhibition. *Bioorg Med Chem*, **2010**, *18*(22), 7940-7947.
- 806 [89] Nguyen, T.T.; Woo, H.J.; Kang, H.K.; Nguyen, V.D.; Kim, Y.M.; Kim, D.W.; Ahn, S.A.; Xia, Y.; Kim,
807 D. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in *Pichia*
808 *pastoris*. *Biotechnol Lett*, **2012**, *34*(5), 831-838.
- 809 [90] Chen, F.; Chan, K.H.; Jiang, Y.; Kao, R.Y.; Lu, H.T.; Fan, K.W.; Cheng, V.C.; Tsui, W.H.; Hung, I.F.;
810 Lee, T.S.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. In vitro susceptibility of 10 clinical isolates of SARS
811 coronavirus to selected antiviral compounds. *J Clin Virol*, **2004**, *31*(1), 69-75.
- 812 [91] Juillet, G. In *Low-cost dexamethasone reduces death by up to one third in hospitalised patients*
813 *with severe respiratory complications of COVID-19*; Oxford University: Oxford, **2020**.
- 814 [92] Wan, S.; Yi, Q.; Fan, S.; Lv, J.; Zhang, X.; Guo, L.; Lang, C.; Xiao, Q.; Xiao, K.; Yi, Z.; Qiang, M.;
815 Xiang, J.; Zhang, B.; Chen, Y. Characteristics of lymphocyte subsets and cytokines in peripheral
816 blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). *medRxiv*,
817 **2020**, 2020.2002.2010.20021832.
- 818 [93] Nidorf, S.M.; Thompson, P.L. Why Colchicine Should Be Considered for Secondary Prevention
819 of Atherosclerosis: An Overview. *Clin Ther*, **2019**, *41*(1), 41-48.
- 820 [94] Kontzias, A.; Kotlyar, A.; Laurence, A.; Changelian, P.; O'Shea, J.J. Jakinibs: a new class of kinase
821 inhibitors in cancer and autoimmune disease. *Curr Opin Pharmacol*, **2012**, *12*(4), 464-470.
- 822 [95] Stebbing, J.; Phelan, A.; Griffin, I.; Tucker, C.; Oechsle, O.; Smith, D.; Richardson, P. COVID-19:
823 combining antiviral and anti-inflammatory treatments. *Lancet Infect Dis*, **2020**, *20*(4), 400-402.
- 824 [96] Favalli, E.G.; Biggioggero, M.; Maioli, G.; Caporali, R. Baricitinib for COVID-19: a suitable
825 treatment? *Lancet Infect Dis*, **2020**.
- 826 [97] Richardson, P.J.; Corbellino, M.; Stebbing, J. Baricitinib for COVID-19: a suitable treatment? -
827 Authors' reply. *Lancet Infect Dis*, **2020**.
- 828 [98] Vlahakos, D.; Arkadopoulos, N.; Kostopanagiotou, G.; Siasiakou, S.; Kaklamanis, L.; Degiannis,
829 D.; Demonakou, M.; Smyrniotis, V. Deferoxamine attenuates lipid peroxidation, blocks
830 interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers
831 renoprotection after acute hepatic ischemia in pigs. *Artif Organs*, **2012**, *36*(4), 400-408.
- 832 [99] Cheng, Y.; Wang, H.; Mao, M.; Liang, C.; Zhang, Y.; Yang, D.; Wei, Z.; Gao, S.; Hu, B.; Wang, L.;
833 Cai, Q. Escin Increases the Survival Rate of LPS-Induced Septic Mice Through Inhibition of
834 HMGB1 Release from Macrophages. *Cell Physiol Biochem*, **2015**, *36*(4), 1577-1586.
- 835 [100] Carr, A.C.; Maggini, S. Vitamin C and Immune Function. *Nutrients*, **2017**, *9*(11).

- [101] Bakaev, V.V.; Duntau, A.P. Ascorbic acid in blood serum of patients with pulmonary tuberculosis and pneumonia. *Int J Tuberc Lung Dis*, **2004**, *8*(2), 263-266.
- [102] Mochalkin, N.I. [Ascorbic acid in the complex therapy of acute pneumonia]. *Voen Med Zh*, **1970**, *9*, 17-21.
- [103] Atherton, J.G.; Kratzing, C.C.; Fisher, A. The effect of ascorbic acid on infection chick-embryo ciliated tracheal organ cultures by coronavirus. *Arch Virol*, **1978**, *56*(3), 195-199.
- [104] Davelaar, F.G.; Bos, J. Ascorbic acid and infectious bronchitis infections in broilers. *Avian Pathol*, **1992**, *21*(4), 581-589.
- [105] McKibbin, W.; Fernando, R. *The Global Macroeconomic Impacts of COVID-19: Seven Scenarios*; Australian National University, The Brookings Institution, Centre of Excellence in Population Ageing Research (CEPAR) **2020**.
- [106] Young, L. World not prepared for the next big pandemic: report. <https://globalnews.ca/news/5914803/world-not-prepared-pandemic/> (Accessed April 24, 2020).
- [107] Walsh, B. The World Is Not Ready for the Next Pandemic. <https://time.com/magazine/us/4766607/may-15th-2017-vol-189-no-18-u-s/> (Accessed April 24, 2020).
- [108] Sanger, D.E.; Lipton, E.; Sullivan, E.; Crowley, M. Before Virus Outbreak, a Cascade of Warnings Went Unheeded. <https://www.nytimes.com/2020/03/19/us/politics/trump-coronavirus-outbreak.html> (Accessed April 24, 2020).
- [109] Gautret, P.; Lagier, J.-C.; Parola, P.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Dupont, H.T. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents*, **2020**, 105949.
- [110] Gautret, P.; Lagier, J.C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Sevestre, J.; Mailhe, M.; Doudier, B.; Aubry, C.; Amrane, S.; Seng, P.; Hocquart, M.; Eldin, C.; Finance, J.; Vieira, V.E.; Dupont, H.T.; Honore, S.; Stein, A.; Million, M.; Colson, P.; La Scola, B.; Veit, V.; Jacquier, A.; Deharo, J.C.; Drancourt, M.; Fournier, P.E.; Rolain, J.M.; Brouqui, P.; Raoult, D. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. *Travel Med Infect Dis*, **2020**, 101663.
- [111] Marcus, A. Hydroxychloroquine-COVID-19 study did not meet publishing society's "expected standard". <https://retractionwatch.com/2020/04/06/hydroxychlorine-covid-19-study-did-not-meet-publishing-societys-expected-standard/> (Accessed April 21, 2020).
- [112] Feuerstein, A.; Herper, M. Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment. <https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/> (Accessed April 21, 2020).
- [113] Lippi, G.; Mattiuzzi, C.; Bovo, C.; Plebani, M. Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). *Acta Biomed*, **2020**, *91*(2), 137-145.
- [114] Wolters, F.; van de Bovenkamp, J.; van den Bosch, B.; van den Brink, S.; Broeders, M.; Chung, N.H.; Favie, B.; Goderski, G.; Kuijpers, J.; Overvest, I.; Rahamat-Langedoen, J.; Wijsman, L.; Melchers, W.J.; Meijer, A. Multi-center evaluation of cepheid xpert(R) xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic. *J Clin Virol*, **2020**, *128*, 104426.
- [115] van Kasteren, P.B.; van der Veer, B.; van den Brink, S.; Wijsman, L.; de Jonge, J.; van den Brandt, A.; Molenkamp, R.; Reusken, C.; Meijer, A. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. *J Clin Virol*, **2020**, *128*, 104412.
- [116] Kruttgen, A.; Cornelissen, C.G.; Dreher, M.; Hornef, M.; Imohl, M.; Kleines, M. Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. *J Clin Virol*, **2020**, *128*, 104394.

- 886 [117] Nelson, P.P.; Rath, B.A.; Fragkou, P.C.; Antalis, E.; Tsiodras, S.; Skevaki, C. Current and Future
887 Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives. *Front*
888 *Cell Infect Microbiol*, **2020**, *10*, 181.
- 889 [118] LeBlanc, J.J.; Gubbay, J.B.; Li, Y.; Needle, R.; Arneson, S.R.; Marcino, D.; Charest, H.; Desnoyers,
890 G.; Dust, K.; Fattouh, R.; Garceau, R.; German, G.; Hatchette, T.F.; Kozak, R.A.; Krajden, M.;
891 Kuschak, T.; Lang, A.L.S.; Levett, P.; Mazzulli, T.; McDonald, R.; Mubareka, S.; Prystajec, N.;
892 Rutherford, C.; Smieja, M.; Yu, Y.; Zahariadis, G.; Zelyas, N.; Bastien, N.; Group, C.-
893 P.D.I.T.o.t.C.P.H.L.N.R.V.W. Real-time PCR-based SARS-CoV-2 detection in Canadian
894 Laboratories. *J Clin Virol*, **2020**, 104433.
- 895 [119] Smithgall, M.C.; Scherberkova, I.; Whittier, S.; Green, D.A. Comparison of Cepheid Xpert
896 Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. *J Clin Virol*,
897 **2020**, *128*, 104428.
- 898 [120] Merindol, N.; Pepin, G.; Marchand, C.; Rheault, M.; Peterson, C.; Poirier, A.; Houle, C.;
899 Germain, H.; Danylo, A. SARS-CoV-2 detection by direct rRT-PCR without RNA extraction. *J Clin*
900 *Virol*, **2020**, *128*, 104423.
- 901 [121] Xiang, X.; Qian, K.; Zhang, Z.; Lin, F.; Xie, Y.; Liu, Y.; Yang, Z. CRISPR-Cas Systems Based
902 Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus
903 (COVID-19) Pneumonia. *J Drug Target*, **2020**, 1-10.
- 904 [122] Morales-Narvaez, E.; Dincer, C. The impact of biosensing in a pandemic outbreak: COVID-19.
905 *Biosens Bioelectron*, **2020**, *163*, 112274.
- 906 [123] Roser, M.; Ritchie, H.; Ortiz-Ospina, E.; Hasell, J. Coronavirus Pandemic (COVID-19).
907 <https://ourworldindata.org/grapher/full-list-total-tests-for-covid-19?time=2020-05-18&country=ARG+AUT+BGD+BEL+BRA+CAN+COL+HRV+CZE+ECU+EST+FIN+DEU+Ghana%2C%20samples%20tested+HKG+ISL+India%2C%20people%20tested+IRN+ISR+Italy%2C%20people%20tested+Japan%2C%20tests%20performed+KEN+MYS+LTU+MAR+NPL+NOR+NZL+PAN+PER+POL+QAT+RUS+SAU+SRB+Singapore%2C%20swabs%20tested+SVN+KOR+SWE+TWN+Thailand%2C%20people%20tested+TUR+UKR+United%20Kingdom%2C%20tests%20performed+United%20States%2C%20tests%20performed+VNM+ZWE+URY+USA+GBR+UGA+TUN+THA+CHE+ESP+ZAF+SVK+SGP+SEN+RWA+ROU+PRT+PHL+PRY+PAK+NGA+NLD+MMR+MEX+LUX+KAZ+JPN+LVA+ITA+IRL+IDN+IND+GRC+HUN+GHA+FRA+ETH+SLV+DNK+CUB+CRI+CHL+BGR+BOL+BLR+BHR+AUS>
914 (Accessed April 21, 2020).
- 917 [124] Cogan, J.F.; Shultz, G.P. Remdesivir Affirms the American Way.
918 <https://www.wsj.com/articles/remdesivir-affirms-the-american-way-11588368750>
919 (Accessed May 19, 2020).
- 920 [125] ICER ICER Presents Alternative Pricing Models for Remdesivir as a Treatment for COVID-19.
921 https://icer-review.org/announcements/alternative_pricing_models_for_remdesivir/
922 (Accessed May 19, 2020).
- 923 [126] Hill, A.M.; Barber, M.J.; Gotham, D. Estimated costs of production and potential prices for the
924 WHO Essential Medicines List. *BMJ Glob Health*, **2018**, *3*(1), e000571.
- 925 [127] Hill, A.; Wang, J.; Levi, J.; Heath, K.; Fortunak, J. Minimum costs to manufacture new
926 treatments for COVID-19. *J Virus Erad*, **2020**, *6*(2), 61-69.
- 927 [128] Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Duan, Y.; Yu, J.;
928 Wang, L.; Yang, K.; Liu, F.; You, T.; Liu, X.; Yang, X.; Bai, F.; Liu, H.; Liu, X.; Guddat, L.W.; Xiao,
929 G.; Qin, C.; Shi, Z.; Jiang, H.; Rao, Z.; Yang, H. Structure-based drug design, virtual screening
930 and high-throughput screening rapidly identify antiviral leads targeting COVID-19. *bioRxiv*,
931 **2020**, 2020.2002.2026.964882.
- 932 [129] Strain-Damerell, C.; Owen, D.; Lukacik, P.; Douangamath, A.; Fearon, D.; Powell, A.; Dias, A.;
933 Resnick, E.; Gehrtz, P.; Reddi, R.; Wild, C.; Krojer, T.; Skyner, R.; Carbery, A.; Brandao-Neto, J.;
934 Dunnett, L.; Williams, M.; Aragao, D.; Crawshaw, A.; Mazzorana, M.; McAuley, K.; Flaig, R.;
935 Hall, D.; Stuart, D. Main protease structure and XChem fragment screen.

- <https://www.diamond.ac.uk/covid-19/for-scientists/Main-protease-structure-and-XChem.html> (Accessed April 21, 2020).
- [130] Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; O'Meara, M.J.; Guo, J.Z.; Swaney, D.L.; Tummino, T.A.; Huettenhain, R.; Kaake, R.M.; Richards, A.L.; Tutuncuoglu, B.; Foussard, H.; Batra, J.; Haas, K.; Modak, M.; Kim, M.; Haas, P.; Polacco, B.J.; Braberg, H.; Fabius, J.M.; Eckhardt, M.; Soucheray, M.; Bennett, M.J.; Cakir, M.; McGregor, M.J.; Li, Q.; Naing, Z.Z.C.; Zhou, Y.; Peng, S.; Kirby, I.T.; Melnyk, J.E.; Chorba, J.S.; Lou, K.; Dai, S.A.; Shen, W.; Shi, Y.; Zhang, Z.; Barrio-Hernandez, I.; Memon, D.; Hernandez-Armenta, C.; Mathy, C.J.P.; Perica, T.; Pilla, K.B.; Ganesan, S.J.; Saltzberg, D.J.; Ramachandran, R.; Liu, X.; Rosenthal, S.B.; Calviello, L.; Venkataramanan, S.; Liboy-Lugo, J.; Lin, Y.; Wankowicz, S.A.; Bohn, M.; Sharp, P.P.; Trenker, R.; Young, J.M.; Caverio, D.A.; Hiatt, J.; Roth, T.L.; Rathore, U.; Subramanian, A.; Noack, J.; Hubert, M.; Roesch, F.; Vallet, T.; Meyer, B.; White, K.M.; Miorin, L.; Rosenberg, O.S.; Verba, K.A.; Agard, D.; Ott, M.; Emerman, M.; Ruggero, D.; García-Sastre, A.; Jura, N.; von Zastrow, M.; Taunton, J.; Ashworth, A.; Schwartz, O.; Vignuzzi, M.; d'Enfert, C.; Mukherjee, S.; Jacobson, M.; Malik, H.S.; Fujimori, D.G.; Ideker, T.; Craik, C.S.; Floor, S.; Fraser, J.S.; Gross, J.; Sali, A.; Kortemme, T.; Beltrao, P.; Shokat, K.; Shoichet, B.K.; Krogan, N.J. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. *bioRxiv*, **2020**, 2020.2003.2022.002386.
- [131] Lee, A.; Robinson, M. Contribute your expertise to design inhibitors of the SARS-CoV-2 main protease. <https://postera.ai/covid> (Accessed April 21, 2020).
- [132] Young, N.; Saperia, E. Crowdsourcing ideas to combat COVID-19. <https://www.nesta.org.uk/blog/crowdsourcing-ideas-combat-covid-19/> (Accessed April 21, 2020).

962 **Figure 1.** The SARS-CoV-2 virus infection cycle.

Figure 2. Different drug targets of SARS-CoV-2 that are currently being explored. A) Spike protein, B) spike protein-ACE2 docking interface (PDB ID 6LZG), C) main protease (PDB ID 6Y2E) and D) Nsp15 ribonuclease (PDB ID 6VWW).

Umifenovir

Nitric oxide

Figure 3. Spike protein targeting drugs umifenovir and nitric oxide.

Captopril

Lisinopril

Enalapril

Perindopril

Ramipril

Trandolapril

Fosinopril

Quinapril

Benazepril

Figure 4. Structures of representative ACEIs.

Irbesartan

Candesartan

Eprosartan

Losartan

Olmesartan

Telmisartan

Valsartan

974

975 **Figure 5.** Structures of representative ARBs.

976

Glycyrrhizin

977

978 **Figure 6.** Structure of Chinese herbal medicine glycyrrhizin.

979

Chloroquine

Hydroxychloroquine

980

981 **Figure 7.** Endosome-targeting drugs chloroquine and hydroxychloroquine.

982

983

Camostat

Aloxistatin

984 **Figure 8.** Small-molecule therapies that target host proteases.

985

Favipiravir

Ribavirin

Remdesivir

986

987 **Figure 9.** Small-molecule therapies that target SARS-CoV-2 RNA-dependent RNA polymerase.

988

Lopinavir

Ritonavir

989

990 **Figure 10.** Small-molecule therapies that target SARS-CoV-2 M^{pro}.

991

Quercetin

Baicalin

992

Figure 11. Structures of quercetin and baicalin.

Figure 12. Corticosteroids being assessed for treatment of COVID-19-associated pneumonia.

Figure 13. Cytokine production inhibitors being assessed for treatment of COVID-19-associated ARDS.

Clopidogrel

Rivaroxaban

Atorvastatin

Omeprazole

Ibuprofen

Naproxen

Aspirin

Indometacin

Sildenafil

Thalidomide

Fingolimod

Pirfenidone

Vitamin C

Figure 14. Cardioprotective medicines being trialled in COVID-19 patients.

Figure 15. Other drugs being assessed for treatment of COVID-19-associated ARDS.